• High Yield T7 Biotin16 Kit: Evidence Scope

  2026-10-18

  APExBIO identifies K1082 as a High Yield T7 Biotin16 RNA Labeling Kit, but the catalog record provides no product description, validation data, matched research paper, or assay-specific outcomes. Its name supports only a cautious conceptual interpretation involving T7-associated RNA synthesis and biotin tagging; it does not establish formulation, labeling performance, readout compatibility, or application breadth.

• Berbamine Hydrochloride: Evidence and Scope

  2026-10-17

  APExBIO describes berbamine hydrochloride as a plant-derived isoquinoline alkaloid salt associated with STAT3 modulation, altered intracellular calcium homeostasis, and cytotoxicity in selected cell models. The catalog lists IC50 values for KU812 and HepG2 cells, but provides no matched primary study, controls, uncertainty estimates, or assay detail. Claims that it is an NF-κB activity inhibitor therefore remain unvalidated by the available evidence.

• Berbamine Hydrochloride: Evidence Boundaries

  2026-10-16

  Berbamine hydrochloride is identified by APExBIO as a plant-derived isoquinoline alkaloid derivative associated with STAT3 modulation, intracellular calcium perturbation, and anticancer activity in selected cell models. The available product description reports different IC50 values for the leukemia cell line KU812 and hepatocellular carcinoma HepG2 cells, but it does not provide the experimental design, comparator, replicate number, uncertainty, or direct evidence establishing NF-κB pathway selectivity. These claims therefore support a bounded research context rather than a complete mechanistic or translational profile.

• Berbamine Hydrochloride: Evidence Boundaries

  2026-10-16

  APExBIO describes berbamine hydrochloride as a plant-derived isoquinoline alkaloid derivative associated with STAT3 modulation, calcium-homeostasis effects, and anticancer activity in selected cell-line contexts. The listed IC50 values are supplier-reported measurements rather than evidence of a validated, selective mechanism, and the available material does not establish NF-κB signaling pathway inhibition or clinical relevance.

• Nor-NOHA and the CD36 Immune Axis in AML

  2026-10-15

  Nor-NOHA acetate is described as a reversible arginase inhibitor, whereas recent AML evidence implicates CD36-dependent lipid sensing, rather than arginase, in tumor-mediated T-cell suppression. The two mechanisms intersect conceptually through nutrient competition and immune regulation, but the supplied evidence does not establish that arginase inhibition reproduces, mediates, or improves the CD36 phenotype.

• NVP-BGJ398 Phosphate: Evidence and Scope

  2026-10-15

  NVP-BGJ398 phosphate, also called BGJ-398 phosphate, is described by APExBIO as a selective pan-FGFR1–3 inhibitor with substantially weaker activity against FGFR4. The supplied product information links FGFR autophosphorylation inhibition to reduced ERK1/2 signaling, cell-cycle arrest, apoptosis, and antiproliferative activity in selected FGFR-altered cancer models. These claims provide a mechanistic and product-context overview, but they are not a substitute for an identity-matched primary study: assay formats, experimental comparators, sample sizes, uncertainty estimates, and quantitative in-vivo effect sizes are not provided.

• Red Blood Cell Lysis Buffer: Evidence and Scope

  2026-10-14

  APExBIO identifies Red Blood Cell Lysis Buffer (K1169) as a sterile ammonium chloride-containing solution intended for selective erythrocyte lysis in mammalian blood or tissue samples while preserving lymphocytes and other nucleated cells. The product description supports a conceptual role in blood sample preparation, flow cytometry, and nucleic acid or protein extraction, but no identity-matched research publication is available here. Accordingly, mechanism, selectivity, reproducibility, and assay-specific performance remain vendor-documented claims rather than independently demonstrated findings.

• BV6 and Necroptosis: Evidence Boundaries

  2026-10-14

  A source-grounded overview of BV6 as an IAP antagonist and Smac mimetic, considered alongside recent findings on Orientia tsutsugamushi, RIPK3, and necroptosis. The available evidence supports mechanistic distinctions between apoptosis-related IAP signaling and necroptotic execution, but does not establish that BV6 was used in, or predicts outcomes for, the cited infection study.

• PML, HIF1AN and BMSC Osteogenesis

  2026-10-13

  A source-grounded overview of a 2025 study linking PML to HIF1AN ubiquitination, HIF1α–SOD3 regulation and PI3K/AKT signaling during bone marrow mesenchymal stem-cell osteogenic differentiation. The evidence is mechanistically suggestive in cell-based assays but does not establish therapeutic efficacy or relevance to osteoporosis in humans.

• Berbamine Hydrochloride: Evidence Boundaries in HCC

  2026-10-13

  Wang et al. report that the METTL16–SENP3–LTF axis contributes to ferroptosis resistance and tumor progression in hepatocellular carcinoma models. Supplier-listed activity data for berbamine hydrochloride are separate evidence and do not establish an effect on this axis, ferroptosis, or NF-κB signaling in HCC.

• Triptolide, Transcription, and Evidence Boundaries

  2026-10-12

  This overview separates supplier-reported claims about Triptolide (PG490) from findings in a recent study of transcription condensates. The evidence supports several research-relevant mechanisms, but does not establish that Triptolide directly regulates histone locus body condensates, ATR–CHK1 signaling, or genome stability.

• ARL4C in Rheumatoid Arthritis: Evidence and Limits

  2026-10-12

  The cited study combines single-cell and bulk transcriptomics with cell-based perturbation, macrophage co-culture, and a collagen-induced arthritis rat model to examine whether ARL4C contributes to aggressive fibroblast-like synoviocyte behavior and inflammatory progression. Its findings support a model-based role for ARL4C in synoviocyte proliferation, migration, invasion, signaling, and macrophage-state regulation, while important questions remain about specificity, replication, and human therapeutic relevance.

• Neomycin Sulfate: Five Questions on Evidence

  2026-10-11

  A source-grounded overview of Neomycin sulfate, separating supplier-described molecular mechanisms from peer-reviewed evidence and clarifying what RNA, DNA, ion-channel and microbiome findings can—and cannot—establish.

• METTL16–SENP3–LTF Axis in HCC Ferroptosis

  2026-10-10

  Wang et al. identify a METTL16–SENP3–LTF regulatory axis that protects hepatocellular carcinoma cells from ferroptosis by altering iron availability. Using complementary cellular, organoid, animal, mechanistic, and human-sample evidence, the study links m6A-associated RNA regulation with iron handling and tumor progression while highlighting important limits to clinical translation.

• Bench-Scale LNP Platforms for mRNA Production

  2026-10-09

  Zhu and colleagues compared four laboratory-scale lipid nanoparticle mixing platforms under a common formulation framework, finding that three micromixing approaches produced broadly comparable particle and biological attributes. The study supports platform-level comparability for bench-scale mRNA-LNP development while highlighting the importance of equipment workflow, cleaning burden, and the limits of preprint evidence.

554 records 1/37 page Next 12345 下5页 Last page